Human SARS-CoV-2 hCoV-19/France/GES-IPP04895/2024, lineage KP.2

REFERENCE STRAIN


EVAg

Produced by
: IP
Shipping From
: Paris - FR

Product Description

Ref-SKU:
017V-05966
Infectious cell culture supernatant of human SARS-CoV-2, lineage KP.2
Product Risk Group: 
Virus name: 
Strain: 

Storage conditions: 
Viral Storage Medium -80C
Sequencing: 
Complete genome
Infectivity: 
Infectivity tested
Mycoplasmic content: 
Not tested

Unit definition: 
one vial

In stock

2 000,00 €
(Cost per access for Academics)

catalogue

biobank

Portal

EVAg

purchase

buy

order

price

cost

shipping

shipment

experiment

research

laboratory

viral

virus

Special feature: 
GMO: 
No
Biosafety restrictions: 
BSL3 biosafety procedures
Virus host type: 
Infectivity Test: 
1,56E+05 PFU/mL
Production cell line: 
Virus Cultivability: 
Passage: 
C2
Shipping conditions: 
IATA Classification: 

Information about the collection of the virus

Recombinant product: 
No
Biological material origin: 
Natural origin
Collection date: 
Thursday, 21 March, 2024
Country of collection: 
Isolation host: 
Isolation technique: 
MOI 10-4










Comments (1)

  • Belinda Carnasciali's picture

    VisMederi, a medium research enterprise based in Italy, would like to acquire the present KP.2 SARS-COV-2 variant with the aim to set-up, standardize and validate a new high through-put microneutralization assay for the determination and semi-quantitation of neutralizing antibodies in human and animal samples. The scientific aim of the study would be to investigate the immunological mechanisms of protection and, the viral escape from the immunity elicited by means of previous exposure and/or vaccination. The study is a follow up of previous projects aimed to assess the persistence of neutralizing antibodies towards SARS-COV-2 Omicron sublineage after the third vaccine dose. (doi: 10.1016/j.actatropica.2023.107042).

    Jun 20, 2024